Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease

@article{Antonini2007FibroticHR,
  title={Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease},
  author={Angelo Antonini and Werner Poewe},
  journal={The Lancet Neurology},
  year={2007},
  volume={6},
  pages={826-829}
}
BACKGROUND Retroperitoneal and pleuropulmonary fibrosis are well known but rare complications of the treatment of Parkinson's disease with ergolinic dopamine agonists; however, until now, these complications have not substantially affected the routine clinical use of these drugs. The occurrence of restrictive valvular heart disease during treatment with pergolide and cabergoline caused concern about the safety of dopamine agonists in Parkinson's disease. Specifically, there is uncertainty… Expand
Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson’s disease
TLDR
The excessive dose of cabergoline in this case suggests a dose dependent effect on the development of cardiac fibrosis, which has been suggested for pergolide before [6]. Expand
Valvular Heart Disease in Patients with Prolactinomas on Cabergoline Treatment
TLDR
Cabergoline at doses commonly used in patients with prolactinomas not associated with higher prevalence of clinically significant valvular regurgitation and a correlation between cumulative dose of cabergoline and mitral valve thickness is found. Expand
Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease
TLDR
The case of a 68-year-old man who received pergolide for 2 years for Parkinson's disease, who developed retroperitoneal fibrosis resulting in renal failure from ureteral obstruction necessitating ureTERal stenting, as well as significant aortic and mitral valve insufficiency, is described. Expand
Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly.
TLDR
The case is reported of a female patient with acromegaly who had been taking low-dose cabergoline for one year, and presented with signs and symptoms of right-sided heart failure, and echocardiography revealed a thickened and retracted tricuspid valve associated with severe tric Suspid regurgitation and enlargement of the right-heart chambers. Expand
Carcinoid heart disease.
TLDR
A recent analysis of 200 cases demonstrated an increase in median survival from 1.5 years to 4.4 years in the last two decades, and a robust correlation between diminution of circulating tumor products and an increased long-term survival in CHD has not been rigorously demonstrated. Expand
Carcinoid heart disease.
TLDR
A robust correlation between diminution of circulating tumor products and an increased long-term survival in CHD has not been rigorously demonstrated, but technical advances as well as an earlier diagnosis have decreased surgical mortality to <10% and valve replacements are undertaken more frequently. Expand
Dopamine agonists and valvular heart disease
TLDR
Dopamine agonist doses in prolactinoma therapy are 10-fold lower than those employed in Parkinson's disease, although occasionally dopamine agonist-resistant patients require higher doses, and the risk for valvulopathy appears low. Expand
Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
TLDR
Owing to the persistence of risk of heart valve damage over time and the lack of its mid-term reversibility in many patients, pergolide and cabergoline should be prescribed only when therapeutic alternatives with a better risk/benefit ratio are unavailable and the patient has access to echocardiography. Expand
Drug-induced fibrotic valvular heart disease
TLDR
Results from clinical trials show that drug dose and treatment duration affect both the risk of developing the disease and its severity, and continued vigilance is necessary because several commonly prescribed treatments interact with serotonergic pathways. Expand
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
TLDR
The clinical significance of the present findings has yet to be confirmed by future larger prospective studies with rigorous echocardiographic protocols and prolonged duration of follow-up, but one study found an increased rate of moderate tricuspid regurgitation. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
TLDR
The frequency of clinically important valve regurgitation was significantly increased in Patients taking pergolide or cabergoline, but not in patients taking non-ergot-derived dopamine agonists, as compared with control subjects. Expand
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
TLDR
Clinicians should consider changing to a non-ergot drug if this disease is diagnosed, and pergolide treatment was stopped because of restrictive valvular heart disease, in six patients, in two of whom regression of disease was shown. Expand
Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study
TLDR
Increased frequencies of valvular regurgitation in patients treated with the ergot agonists pergolide and cabergoline are shown in comparison to both normal controls and patients treating with nonergot agonists. Expand
Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists
TLDR
This study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves but identified a positive correlation between the daily dose of pergolide and the tenting area of the mitral valve and other valvular parameters were not found to correlate with the age, disease duration, treatment duration, or dosage of medication. Expand
Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson’s disease patients treated with cabergoline
TLDR
A retrospective study of Parkinson’s disease patients on chronic cabergoline monotherapy or adjunctive treatment to identify symptoms suggestive of pleuro-pulmonary, cardiac or retroperitoneal fibrosis suggests a low risk of fibrotic side effects with Cabergoline, particularly cardiac valvulopathy. Expand
Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
TLDR
Data from a case-control study of echocardiographic findings of valve function in patients receiving dopamine agonists for PD strengthen the conclusion that pergolide contributes to cardiac valve regurgitation when used in the long term as a treatment for PD. Expand
Dopamine agonists and the risk of cardiac-valve regurgitation.
TLDR
Use of the dopamine agonists pergolide and cabergoline was associated with an increased risk of newly diagnosed cardiac-valve regurgitation. Expand
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader‐blinded monocenter echocardiography study
TLDR
The data suggest that ergot DAs are associated with higher prevalence of VHD compared to non‐ergot DAs and controls, and standard echocardiography seems sufficient to detect VHD in PD patients treated with DAs. Expand
Fibrosis associated with dopamine agonist therapy in Parkinson's disease.
TLDR
The results indicate, to a certain extent, that the relative risk for onset of dopamine agonist-related fibrotic syndromes is lower particularly for pramipexole and lisuride, which have been available for more years than pramipesxole. Expand
Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
TLDR
The results indicate that high cumulative dose and long-term treatment with cabergoline are risk factors for valvulopathy in patients with Parkinson disease. Expand
...
1
2
3
...